JP2012505905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505905A5 JP2012505905A5 JP2011532217A JP2011532217A JP2012505905A5 JP 2012505905 A5 JP2012505905 A5 JP 2012505905A5 JP 2011532217 A JP2011532217 A JP 2011532217A JP 2011532217 A JP2011532217 A JP 2011532217A JP 2012505905 A5 JP2012505905 A5 JP 2012505905A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkoxy
- alkyl
- pattern
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000002245 particle Substances 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims 2
- 230000036765 blood level Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- -1 cyano, hydroxy, acetyl Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 102000006991 Apolipoprotein B-100 Human genes 0.000 claims 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10648308P | 2008-10-17 | 2008-10-17 | |
| US61/106,483 | 2008-10-17 | ||
| PCT/US2009/060679 WO2010045361A1 (en) | 2008-10-17 | 2009-10-14 | Methods of reducing small, dense ldl particles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505905A JP2012505905A (ja) | 2012-03-08 |
| JP2012505905A5 true JP2012505905A5 (enExample) | 2012-11-29 |
| JP5694941B2 JP5694941B2 (ja) | 2015-04-01 |
Family
ID=42106878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532217A Active JP5694941B2 (ja) | 2008-10-17 | 2009-10-14 | 小型高密度ｌｄｌ粒子を減少させる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20100152295A1 (enExample) |
| EP (1) | EP2346498B1 (enExample) |
| JP (1) | JP5694941B2 (enExample) |
| KR (1) | KR20110091680A (enExample) |
| CN (1) | CN102209532B (enExample) |
| BR (1) | BRPI0920170A2 (enExample) |
| CA (1) | CA2740874C (enExample) |
| ES (1) | ES2712052T3 (enExample) |
| MX (1) | MX2011004077A (enExample) |
| TW (1) | TWI491392B (enExample) |
| WO (1) | WO2010045361A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| CN110152000A (zh) | 2011-03-02 | 2019-08-23 | J·深塔格 | 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物 |
| CN105764498A (zh) | 2013-11-20 | 2016-07-13 | 西玛贝医药公司 | 纯合家族型高胆固醇血症的治疗 |
| SI3119384T1 (sl) | 2014-03-20 | 2018-12-31 | Cymabay Therapeutics, Inc. | Zdravljenje intrahepatičnih holestatičnih bolezni |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| HRP20192299T1 (hr) | 2014-04-11 | 2020-03-06 | Cymabay Therapeutics, Inc. | Liječenje nafld i nash |
| MY192385A (en) * | 2016-10-05 | 2022-08-18 | Mitobridge Inc | Methods of treating acute kidney injury |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES494769A0 (es) | 1979-09-05 | 1981-07-16 | Glaxo Group Ltd | Un procedimiento para la pre-paracion de fenoxialcoxifenil- derivados. |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| US7576131B2 (en) | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| ATE542805T1 (de) | 2000-08-11 | 2012-02-15 | Nippon Chemiphar Co | Ppar-delta aktivatoren |
| WO2002046154A1 (fr) | 2000-12-05 | 2002-06-13 | Nippon Chemiphar Co., Ltd. | Activateurs $g(d) de recepteur active par un proliferateur du peroxysome |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| EP1399151A4 (en) | 2001-06-11 | 2004-08-04 | Merck & Co Inc | METHOD FOR TREATING INFLAMMABLE DISEASES BY ADMINISTRATING A PPAR DELTA AGONIST |
| GB0121436D0 (en) * | 2001-09-04 | 2001-10-24 | Pfizer Ltd | Biomodulated multiparticulate formulations |
| CA2521175A1 (en) * | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| JPWO2004093910A1 (ja) | 2003-04-22 | 2006-07-13 | アステラス製薬株式会社 | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 |
| US7199259B2 (en) | 2003-06-20 | 2007-04-03 | Metabolex, Inc. | Resolution of α-(phenoxy)phenylacetic acid derivatives |
| ATE542793T1 (de) * | 2003-09-19 | 2012-02-15 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga |
| JP2008500358A (ja) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法 |
| US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
| MY147518A (en) * | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| SI3119384T1 (sl) * | 2014-03-20 | 2018-12-31 | Cymabay Therapeutics, Inc. | Zdravljenje intrahepatičnih holestatičnih bolezni |
| HRP20192299T1 (hr) * | 2014-04-11 | 2020-03-06 | Cymabay Therapeutics, Inc. | Liječenje nafld i nash |
-
2009
- 2009-10-14 JP JP2011532217A patent/JP5694941B2/ja active Active
- 2009-10-14 WO PCT/US2009/060679 patent/WO2010045361A1/en not_active Ceased
- 2009-10-14 EP EP09821200.4A patent/EP2346498B1/en active Active
- 2009-10-14 CN CN200980144827.7A patent/CN102209532B/zh active Active
- 2009-10-14 ES ES09821200T patent/ES2712052T3/es active Active
- 2009-10-14 MX MX2011004077A patent/MX2011004077A/es active IP Right Grant
- 2009-10-14 KR KR1020117011217A patent/KR20110091680A/ko not_active Ceased
- 2009-10-14 CA CA2740874A patent/CA2740874C/en active Active
- 2009-10-14 BR BRPI0920170A patent/BRPI0920170A2/pt not_active Application Discontinuation
- 2009-10-15 US US12/579,996 patent/US20100152295A1/en not_active Abandoned
- 2009-10-16 TW TW098135183A patent/TWI491392B/zh active
-
2016
- 2016-01-13 US US14/995,024 patent/US20160324811A1/en not_active Abandoned
-
2018
- 2018-10-31 US US16/176,349 patent/US11007162B2/en active Active